Email
Print
Gonorrhea Diagnostics Market - Forecast(2024 - 2030)
Gonorrhea Diagnostics Market Overview
The Gonorrhea Diagnostics Market is estimated to reach $13.6 billion by 2028, growing at a CAGR of 8.9% over the forecast period 2023-2028. Gonorrhea is a sexually transmitted infection afflicted by a bacterium that can affect both genders. Most often, gonorrhea impacts the urethra, rectum or throat. The recommended treatment for gonorrhea includes fluoroquinolone and ciprofloxacin. Cephalosporins, ceftriaxone (intramuscular) or cefixime (oral) are the recommended alternatives. However, recent audit data reveal other cephalosporins, including cefuroxime (intramuscular or often oral), that are currently being used to treat gonorrhea. Gonorrhea can also infect the cervix in females. Most frequently, gonorrhea is spread through vaginal, oral or anal intercourse. But after childbirth, newborns of infected mothers can contract the disease. Gonorrhea most frequently damages the eyes in infants. According to the Women’s Health & STIs article, for vaginal infections, traditional diagnostics leave up to 40% of women with vaginitis undiagnosed after an initial clinical visit.
Gonorrhea Diagnostics Market Report Coverage
The report: “Gonorrhea Diagnostics Market – Forecast
(2023-2028)” by IndustryARC, covers an in-depth analysis of the following
segments in the Gonorrhea Diagnostics Market.
Key Takeaways
- Geographically, North America dominates the Gonorrhea Diagnostics Market in 2022, owing to the rising awareness about the disease.
- The key factor anticipated to drive the Gonorrhea Diagnostics industry in the future is the engagement of multiple sex partners and rapidly changing lifestyles.
- The growth rate of the Gonorrhea diagnostics market size is anticipated to be steady, owing to an increase in hospitals, commercial labs and improved diagnostic methods that are quicker and more cost-effective.
- A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Gonorrhea Diagnostics Market Report.
Gonorrhea Diagnostics Market Segment Analysis – by Diagnostic Type:
Based on Diagnostic Type, Gonorrhea Diagnostics Market
is further segmented into Flow Cytometry, Diagnostic Imaging, Gel
Micro-droplets, Artificial Intelligence, Chromatography, Differential Light
Scattering (DLS), Liposomes, Monoclonal Antibodies, Molecular Diagnostics
Tests and Others. The Molecular Diagnostics segment held the
largest share of the Gonorrhea diagnostics market in 2022, owing to the advantages
associated with it such as ease of performing the procedure, high accuracy and cost
for the performance. It is often necessary to use monoclonal antibody
techniques to determine between gonorrhea and other illnesses that have
overlapping symptoms, which helps in expanding the Gonorrhea Diagnostics market
size.
However, the Flow Cytometry segment is anticipated to grow at the
fastest CAGR of 9.5% over the forecast period 2023-2028. This is due to modern
techniques such as artificial intelligence and diagnostic imaging, which are in the
testing phases. Traditional methods of diagnosis are predicted to be replaced
by newer technologies like flow cytometry for faster and more accurate illness
detection and change the market scenario for the Gonorrhea Diagnostics
industry
Gonorrhea Diagnostics Market Segment Analysis – by End-user:
Based on end-users, the Gonorrhea Diagnostics market is further
segmented into hospitals, laboratory testing, diagnostic centers, clinics,
point-of-care testing and others. The Point-of-care Testing segment held the
largest share of the Gonorrhea diagnostics market in 2022, as the rates of
gonococcal infection and associated costs of untreated infections continued to
increase. According to the Centers for Disease Control (CDC), the rate of
gonococcal infection has increased by 74% despite the availability of highly
sensitive and specific laboratory-based molecular diagnostics tools for the
detection of these Sexually Transmitted Infections (STIs).
However, the Laboratory Testing segment is anticipated to grow at the
fastest CAGR of 9.3% over the forecast period 2023-2028, as most of the cases
of diagnostic testing are carried out in the labs, which is anticipated to
further fuel the Gonorrhea Diagnostics market.
Gonorrhea Diagnostics Market Segment Analysis – by Geography:
Based on Geography, the North American Gonorrhea Diagnostics
Market accounted for 37% of the revenue share in 2022, owing to the
well-developed healthcare infrastructure and favorable government policies
regarding the diagnosis and treatment of Sexually Transmitted Diseases
(STD). According to the Centers for Disease Control (CDC), there are
around 400,000 cases of gonorrhea reported each year in the U.S. The high
awareness level about the disease and favorable reimbursement policies are the
factors anticipated to expand the Gonorrhea diagnostics market size in the
region.
However, the Asia-Pacific region is estimated to grow at the fastest CAGR during the forecast period 2023-2028, owing to the increasing cases of the disease in the region and the number of unmet demands in the market for efficient diagnoses and treatments.
Gonorrhea Diagnostics Market Drivers
Increasing Rates of Sexually Transmitted Infections (STIs):
The Gonorrhea Diagnostics market for Sexually Transmitted Diseases (STD) testing is growing as a result of increased public awareness and patient education. Additionally, it is projected that an expansion of government initiatives, an improvement in patient awareness through education programs and an increase in STI prevalence internationally would fuel market expansion. The prevalence and incidence of STIs have accelerated. According to WHO, more than 1 million Sexually Transmitted Infections (STIs) are acquired every day worldwide, the majority of which are asymptomatic.
The Rising Prevalence and Awareness of the Disease:
Gonorrhea prevalence rates are rising as a result of a number of
factors, including increased public awareness, better access to healthcare,
diagnostic test availability, patterns of resistance, reporting practices and
others. Although gentamicin should not be used as the first line of treatment
for gonorrhea, it may still be beneficial for some people. They may be individuals with isolated genital
infections, people who are allergic to or intolerant to ceftriaxone or ones who
have an infection that is resistant to ceftriaxone. In the past, men were more
likely than women to contract gonorrhea and get treated through chromatography
diagnostics. Over the past few years, the prevalence rate of gonorrhea is
higher in women than in men. According to the Centers for Disease Control (CDC), it
is estimated that among these 8,20,000 new cases, 70% of the population would
be between the ages of 15 and 24. The Centers for Disease Control (CDC) reports
that gonorrhea is more likely to affect women over the age of 25.
Gonorrhea Diagnostics Market Challenge
Rise of Antibiotic-resistant Gonococcal Strains:
The Centers for Disease Control (CDC) restricted the use of
fluoroquinolones in the U.S. as a result of the spread of
fluoroquinolone-resistant Neisseria gonorrhoeae, leaving cephalosporin as the
main risk-free agent for gonorrheal infection. As per the Centers for Disease
Control (CDC), there are around 400,000 cases of gonorrhea reported each year
in the U.S. and approximately 8,20,000 new gonorrhea infections might occur
each year. Out of these, about 30% of new infections are resistant to at least
one antibiotic intended to treat the infection. This narrows the range of
therapy options available to patients, thereby hindering Gonorrhea Diagnostics
market growth.
Gonorrhea Diagnostics Industry Outlook:
Product launches, mergers and acquisitions, joint ventures and
geographical expansions are key strategies adopted by players in the Gonorrhea
Diagnostics Industry. The top 10 companies in the Gonorrhea Diagnostics
Industry are:
- Abbott Laboratories
- Bayer AG
- Merck & Co., Inc.
- Agilent Technologies
- Biomerieux SA
- Danaher Corporation
- Thermo Fisher Scientific
- DiaSorin
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
Recent Developments
- In October 2022, Bayer and the Bill & Melinda Gates Foundation are jointly funding pre-clinical research in the area of novel non-hormonal contraception. This collaboration with the Bill & Melinda Gates Foundation would contribute to expanding access to contraceptive options that address the unmet needs of women worldwide.
- In September 2022, Abbott launched its European Amplatzer™ Talisman™ PFO Occlusion System to treat people who have had a stroke and are at risk of getting another one and have a Patent Foramen Ovale (PFO), a hole in the heart that doesn't shut after birth.
- In
August 2022, Danaher Corporation announced the completion of its
acquisition of Aldevron. It would operate as a standalone operating
company and brand within Danaher's Life Sciences segment.
Relevant Titles
Report Code: HCR 0248
Report Code: HCR 0285
Report Code: HCR 0085
For more Lifesciences and Healthcare Market reports, please click here